GC
HBIO icon

Globeflex Capital’s Harvard Bioscience HBIO Stock Holding History

Globeflex Capital’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,951
Closed -$398K – 499
2024
Q2 		$398K Sell
13,951
-829
-6% -$29.1K 0.04% 267
2024
Q1 		$627K Sell
14,780
-991
-6% -$44.6K 0.06% 233
2023
Q4 		$844K Hold
15,771
– – 0.09% 209
2023
Q3 		$678K Sell
15,771
-961
-6% -$44.3K 0.08% 218
2023
Q2 		$919K Buy
16,732
+3,800
+29% +$209K 0.1% 185
2023
Q1 		$543K Hold
12,932
– – 0.07% 240
2022
Q4 		$358K Sell
12,932
-9,454
-42% -$233K 0.05% 293
2022
Q3 		$573K Hold
22,386
– – 0.1% 237
2022
Q2 		$806K Sell
22,386
-4,461
-17% -$201K 0.2% 155
2022
Q1 		$1.67M Hold
26,847
– – 0.34% 69
2021
Q4 		$1.89M Hold
26,847
– – 0.39% 64
2021
Q3 		$1.87M Buy
26,847
+6,950
+35% +$553K 0.41% 58
2021
Q2 		$1.66M Buy
19,897
+3,383
+20% +$239K 0.3% 103
2021
Q1 		$902K Buy
16,514
+2,671
+19% +$130K 0.16% 204
2020
Q4 		$594K Buy
13,843
+1,797
+15% +$67.1K 0.13% 261
2020
Q3 		$363K Sell
12,046
-887
-7% -$29.8K 0.1% 312
2020
Q2 		$401K Buy
12,933
+2,610
+25% +$70.3K 0.1% 314
2020
Q1 		$228K Buy
10,323
+8,030
+350% +$218K 0.07% 346
2019
Q4 		$70K Hold
2,293
– – 0.01% 441
2019
Q3 		$71K Hold
2,293
– – 0.02% 427
2019
Q2 		$46K Buy
2,293
+713
+45% +$20.9K 0.01% 420
2019
Q1 		$68K Hold
1,580
– – 0.01% 412
2018
Q4 		$50K Hold
1,580
– – 0.01% 412
2018
Q3 		$83K Buy
+1,580
New +$88.7K 0.02% 425
2015
Q4 		– Sell
-17,673
Closed -$668K – 471
2015
Q3 		$668K Hold
17,673
– – 0.14% 250
2015
Q2 		$1.01M Hold
17,673
– – 0.18% 213
2015
Q1 		$1.03M Sell
17,673
-6
-0% -$322 0.2% 215
2014
Q4 		$1M Buy
+17,679
New +$842K 0.19% 216

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Globeflex Capital's HBIO Position: Q3 2024 in Review

Globeflex Capital sold out of Harvard Bioscience (HBIO) in Q3 2024, closing a stake of 13,951 shares — an estimated $398K sold.

Globeflex Capital first reported a position in HBIO in Q4 2014 and held it in 28 quarters. The position peaked at $1.89M in Q4 2021. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2024.

  • Globeflex Capital reported no remaining Harvard Bioscience position as of Q3 2024 after selling out during the quarter.
  • Globeflex Capital sold 13,951 Harvard Bioscience shares in Q3 2024, an estimated $398K.
  • Globeflex Capital first reported a position in Harvard Bioscience in Q4 2014 and held it in 28 quarters.
  • Globeflex Capital's Harvard Bioscience position peaked at $1.89M in Q4 2021.
  • 94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2024.

Based on Globeflex Capital's 13F filing for Q3 2024, filed 13 Nov 2024.